Invesco Biotechnology & Genome ETF (PBE)

The Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that holds a basket of companies working at the frontier of genetic science — gene-editing platforms, diagnostic labs, sequencing equipment makers, and biotech firms developing therapies based on genomic insights. It tracks the NZF Genomics Index, a thematic benchmark focused narrowly on companies whose core business depends on decoding, manipulating, or leveraging human and non-human genetic information.

From genomics hype to an index product

The genomics boom of the late 2010s was part speculation, part genuine breakthrough. After the Human Genome Project’s completion in 2003, the cost of sequencing plummeted from millions of dollars to hundreds, then tens. A wave of startups and established firms rushed to build platforms, services, and therapies around this new frontier. Companies like CRISPR Therapeutics, Illumina, and 10x Genomics became household names in finance circles; investment in the sector surged.

By the early 2020s, sponsors like Invesco created index-based products to let mainstream investors access the theme without picking individual stocks. PBE, tracking the NZF Genomics Index, arrived as a simple vehicle: buy the fund, get a diversified basket of genomics-focused companies, let the index handle the rebalancing. The fund has grown to a meaningful asset base, though it remains far smaller than Invesco’s flagship broad-market products.

What the fund actually holds

The NZF Genomics Index homes in on companies for which genetic science is not peripheral — it is the business. This includes gene-sequencing equipment makers like Illumina and Ion Torrent; companies selling reagents and consumables used in genetic labs; firms developing therapies using CRISPR, RNA interference, or other gene-editing technologies; diagnostics providers offering genetic testing; and bioinformatics platforms that analyze genomic data.

The composition evolves as the sector evolves. Companies that once appeared cutting-edge may fade if their technology loses relevance; new players emerge as the field branches into synthetic biology, long-read sequencing, or other sub-domains. Unlike a stock, which is a single business, PBE is a changing basket, so the specific names inside it shift over time. What remains constant is the thematic thread: you own pieces of companies whose strategy depends on cracking, reading, or rewriting genetic code.

Why someone would buy this fund

The rationale for a genomics-focused fund rests on a simple observation: genetic science is reshaping medicine, agriculture, and some manufacturing, and the companies enabling this shift should benefit disproportionately as it scales. A genomic diagnostics company, for instance, stands to grow as personalized medicine becomes standard; a gene-therapy firm may see returns explode if its candidates move from trials to approved treatments. By holding dozens of these businesses in one fund, you gain exposure to the theme without betting everything on one founder’s vision or one drug candidate’s trial outcome.

This is called thematic or sector investing — narrowing the scope beyond “all public companies” to focus on a particular future that excites you. It comes with both appeal and drawback: the appeal is concentration in what you believe will grow; the drawback is that if the genomics narrative cools, or if progress happens slower than expected, all the holdings suffer together.

Structure, costs, and how to research it

PBE trades like any ETF — it can be bought and sold during market hours on an exchange at a price set by supply and demand. The fund’s expense ratio is quoted qualitatively as reasonable for a thematic product; you can find the exact figure in the fund’s fact sheet on Invesco’s website or through your broker. Because it holds dozens of stocks, it offers diversification within the genomics space, though it has no exposure to broad-market hedges.

As with any ETF, understand that you are making a bet on the index’s composition — you do not get to cherry-pick the companies inside. If you dislike one holding, you must either accept it as part of the basket or avoid the fund. The prospectus and fact sheet lay out the index methodology and the current top holdings, giving you a clear picture of what you would own.

The real risk specific to this fund is concentration risk. If the genomics narrative weakens, funding for biotech dries up, or a major technology platform is disrupted, the whole fund moves in concert. There is no hidden ballast. That is by design — PBE is built for someone convinced genomics will thrive, not for someone hedging against it. It is a bet, not a balanced holding, and should be sized accordingly in a portfolio.

How to dig deeper

Start with the fund’s fact sheet and prospectus, both available on Invesco’s site. The prospectus details the NZF Genomics Index methodology — how many stocks it holds, how it weights them, and what thresholds a company must meet to be included. From there, spend time on the holdings list: scan the names, read a few annual reports from the larger positions, and develop a sense of whether the sector thesis still holds. Look at how the index has fared in different market environments — does it hold up in downturns, or does it amplify losses? Follow earnings calls from major genomics companies to hear where the industry thinks it is going next.

Like any thematic fund, PBE works best for investors who have a conviction about genomics and want simple, passive exposure rather than having to assemble a stock list themselves. It is not a way to time the genomics cycle or beat the index; it is a way to participate in it cheaply and with diversification.